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Abstract
Background: Malaria control strategies emphasize the need for prompt and effective treatment
of malaria episodes. To increase treatment efficacy, Tanzania changed its first-line treatment from
chloroquine to sulphadoxine-pyrimethamine (SP) in 2001. The effect of this policy change on the
availability of antimalarials was studied in rural south-eastern Tanzania.
Methods: In 2001 and 2004, the study area was searched for commercial outlets selling drugs and
their stocks were recorded. Household information was obtained from the local Demographic
Surveillance System.
Results: From 2001 to 2004, the number of general shops stocking drugs increased by 15% and
the number of drug stores nearly doubled. However, the proportion of general shops stocking
antimalarials dropped markedly, resulting in an almost 50% decrease of antimalarial selling outlets.
This led to more households being located farther from a treatment source. In 2004, five out of 25
studied villages with a total population of 13,506 (18%) had neither a health facility, nor a shop as
source of malaria treatment.
Conclusion: While the change to SP resulted in a higher treatment efficacy, it also led to a
decreased antimalarial availability in the study area. Although there was no apparent impact on
overall antimalarial use, the decline in access may have disproportionately affected the poorest and
most remote groups. In view of the imminent policy change to artemisinin-based combination
therapy these issues need to be addressed urgently if the benefits of this new class of antimalarials
are to be extended to the whole population.
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Background
The first and foremost malaria control strategy promoted
by the World Health Organization (WHO) and adopted
by most African countries emphasizes the need for treat-
ment of malaria episodes with an efficacious drug within
24 hours after onset of symptoms [1,2]. African heads of
state agreed at the Abuja summit in April 2000 to ensure
that by 2005 at least 60% of those suffering from malaria
have access to affordable, appropriate and timely treat-
ment [3].
However, in most areas of sub-Saharan Africa, this target
is still far from being reached. Many malaria patients do
not receive prompt and effective treatment for malaria,
even if efficacious drugs are available on the local market
[4-6] or at health facilities [7]. A fever episode, especially
in a child, often prompts action and very high treatment
rates (over 90%) have been reported [8]. On the other
hand, household surveys in 28 African countries have
shown that on average only 42% of children under five
years of age with fever were treated with an antimalarial.
In 80% of these cases chloroquine was used, which can
not be considered any more an efficacious treatment in
most areas [9]. While in case of a malaria attack many fac-
tors influence care seeking behaviour [8], one of the pre-
requisites for successful treatment of a malaria episode is
the availability of effective antimalarial drugs close to
where the episode occurs.
Self-treatment at home is often the first response to a
malaria episode. In many of the studies reviewed by
McCombie [10] self-treatment was frequent in response
to an episode of fever or malaria (44% of the self-treat-
ment rates in published studies were reported to be above
50%). The same review found that almost half of all
malaria episodes were exclusively treated outside the for-
mal health care sector. Hamel [11] reported from a study
in Kenya that 32% of caretakers treated their children's
fever exclusively at home, with an antimalarial. Data
recently collected in our field site in southern Tanzania
suggest that exclusive home treatment is less common,
with 76% of recently feverish children attending a health
facility during their illness. However, not all of those chil-
dren receive an antimalarial when visiting the health facil-
ity.
Reliance on home management and self-treatment raises
crucially the issue of availability of antimalarials. In this
context, the private retail sector has been shown to play an
important role in the provision of drugs close to people's
homes [10,12]. Shops are often preferred as first treatment
choice because of better accessibility, shorter waiting
times, more reliable drug stocks and lower costs [13]. The
role of the retail sector in improving access to prompt
malaria treatment has been recognized by WHO through
its home-management of malaria (HMM) strategy [14].
The national drug policy in Tanzania was strengthened in
2003 when the Tanzania Food, Drugs and Cosmetics Act
established the Tanzania Food and Drugs Authority
(TFDA) as executive agency [15]. Since then the TFDA has
been responsible for all regulatory aspects of drugs and
other medical products in the country. The private retail
sector for drugs includes two types of licensed drug shops
as well as general stores. Mobile drug sellers are not com-
mon in most parts of Tanzania. Fully-fledged Part I phar-
macies are headed by a pharmacist and are allowed to sell
all registered prescription-only (Part I) and over-the-coun-
ter (Part II) drugs. In 2003, there were 344 Part I pharma-
cies in Tanzania, 60% of which were located in Dar es
Salaam, and the rest scattered over other major towns
[16]. Part II drug stores (known as Duka la Dawa Baridi)
need to be staffed with a medically trained vendor and are
allowed to sell over-the-counter drugs such as analgesics/
antipyretics. However, in practice they sell a much wider
variety of drugs. 5,666 Part II drug stores had been regis-
tered in 2003 [16]. According to Goodman (2004)[17],
general shops were formally not allowed to stock any
drugs in 2003 but were in practice permitted to sell com-
mon OTC drugs, such as painkillers. However, the legal
position of drugs in these outlets has been unclear.
Until 2001, chloroquine was the first line antimalarial
and it was designated a Part II drug, available over-the-
counter at Part II drug stores. In practice, chloroquine was
also tolerated in general stores, where it was widely avail-
able [12]. Since the 2001 policy change to sulphadoxine-
pyrimethamine (SP) as first-line treatment and amodi-
aquine as second-line treatment, the first line antimalarial
(but not the second-line) is prescription-only. Hence, SP
can only be purchased legally in Part I pharmacies, besides
being available in health facilities. In many parts of the
country, SP has also been tolerated in Part II drug stores
but not in general shops. These inconsistencies in apply-
ing legal regulations to the use and availability of SP have
resulted in some level of confusion between government
departments and in the development of malaria control
strategies.
The change to SP aimed at increasing the effectiveness of
malaria treatment and hence to decrease the malaria bur-
den. However, little is known so far about the impact of
this policy change in terms of availability of antimalarial
drugs through different providers. Treatment effectiveness
at community level is a function of many interlinked fac-
tors, not just the efficacy of the first line drug. In particular
treatment must be available and accessible to the target
population. This analysis assessed the change in availabil-
ity and accessibility of antimalarial drugs in the private
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sector following the change of first-line treatment in Tan-
zania. The surveys were carried out in a rural Tanzanian
setting in the frame of two projects on (1) access to
malaria treatment (ACCESS Programme) and (2) deploy-
ment of antimalarial combination therapy (Interdiscipli-
nary Monitoring Project for Antimalarial Combination
Therapy in Tanzania – IMPACT-Tz).
Methods
Study area
In 2001 and 2004, we conducted studies on antimalarial
drug availability in the area of a Demographic Surveil-
lance System (DSS) in the Kilombero and Ulanga Districts
in south-eastern Tanzania (Figure 1). The DSS area covers
25 villages (13 in Kilombero and 12 in Ulanga) with
almost 74,000 people (2004) in a highly malaria endemic
floodplain, the Kilombero Valley [18]. Malaria transmis-
sion in the area is intense and perennial with over 300 and
in some areas up to 1,000 infective bites per person per
year but with seasonal fluctuations depending on rainfall
patterns [19] (Killeen, personal communication). Malaria
is the predominant cause of morbidity and mortality,
accounting for about 50% of outpatient diagnoses at rural
health facilities [18]. There were seven health facilities in
the DSS area of Ulanga and another seven in the DSS area
of Kilombero District in 2001 and 2004.
In 2004, the area of Ifakara town was also included in our
studies. This semi-urban headquarters of the Kilombero
District lies in the midst of the floodplain outside the DSS
area. The population included in our studies was 45,700
in 2002 [20]. Malaria transmission is lower here, with a
reported average of 29 infective bites per year [21] and a
decrease in clinical incidence in recent years observed at
Map of Kilombero and Ulanga districts showing Ifakara town and the Demographic Surveillance System (DSS)Figure 1
Map of Kilombero and Ulanga districts showing Ifakara town and the Demographic Surveillance System (DSS).
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the Designated District Hospital [22]. The study area is
described in detail elsewhere [23,24].
Shop surveys
From May to September 2001, the DSS area was searched
for commercial outlets selling drugs, with the help of DSS
field staff familiar with the study area and an outlet inven-
tory from a previous study [12]. All outlets were then vis-
ited by interviewers who recorded the outlets' locations
and their drug stocks. Survey methods are described in
detail elsewhere [17]. Data collection was completed
before the new antimalarial drug policy with SP as first
line drug was implemented in the area.
A further survey was done 3 years after the policy change,
in May – June 2004. The outlet list was updated after con-
sulting village leaders and DSS field staff. All outlets were
visited again by interviewers who geo-located them using
a hand-held GPS unit (Garmin® e-Trex®, Garmin Ltd.) and
administered a questionnaire on drugs stocked, and other
parameters not presented in this paper. In each survey, the
questionnaires contained a checklist for common drug
brand names obtained during pilot studies in local shops.
Drugs were recorded as "in stock" only if the interviewer
was shown the stock. Field supervisors checked the com-
pleted questionnaires and helped to resolve any queries.
In 2004, the survey was extended to Ifakara town, where
the outlets were identified with the help of local commu-
nity leaders.
Follow-up on SP availability
A follow-up study was done in November 2004 to find the
reasons for the low availability of the first-line antimalar-
ial SP. For this purpose, 50 general shops were randomly
sampled from all general shops that had stocked drugs or
had sold drugs previously (n = 474), weighted by the total
number of shops in each of the three sampling units: Kil-
ombero DSS, Ulanga DSS and Ifakara town. A second set
of 50 shops was sampled as backup for shops temporarily
or completely closed down. The shops were visited and a
semi-structured questionnaire was administered to record
stock of SP drugs, customer demand and wholesale
sources for antimalarial drugs; if no SP was stocked, the
reasons for this were elicited.
Household and health facility information
Demographic data as well as household GPS coordinates
were derived from the core DSS database. Since 1997 DSS
field workers have collected basic household information
(births, deaths, migrations) three times per year, i.e. every
household is visited every four months. Locations of DSS
households and health facilities were recorded during
routine DSS data collection and ACCESS Programme
activities. While precise population data were available for
all years, GPS locations of households had been recorded
only once in 2001 and not updated since. GPS data were
available for 12,005 households (total of all households
in 2004: 16,220).
Ethical approval and informed consent
Ethical approval for the studies done within the ACCESS
Programme and IMPACT-Tz was received from the insti-
tutional review board of the Ifakara Health Research and
Development Centre and the Tanzanian National Medical
Research Coordinating Committee (NIMR/HQ/R.8a/
Vol.IX/236). In addition, IMPACT-Tz was approved by the
review board of the U.S. Centers for Disease Control and
Prevention. Participation was voluntary and interviewees
were informed about the purpose and nature of the
research. Oral informed consent was obtained prior to the
interviews. Village authorities of the study area were
informed about all research activities before their onset.
Data entry and analysis
Data were double entered using Microsoft FoxPro and
Microsoft Access (Microsoft Corp. Seattle, USA) and
checked for coding errors and consistency. Intercooled
Stata 8.0 (Stata Corp., College Station, TX, USA) was used
for analysis. Mapping of shops and households was done
using MapInfo Professional 7.0 (MapInfo Corporation).
Results
Drug stocking outlets
In 2001, 350 shops from an initial list of 439 outlets
(80%) were interviewed, of which 287 stocked drugs on
the day of the visit; these comprised 10 Part II drug stores
and 277 general shops, but no Part I pharmacy. Of those
not interviewed, 86 had closed permanently, 1 was tem-
porarily closed, 1 refused, and for 1 no reason was
recorded.
In 2004, 758 commercial outlets were visited, which were
either listed in 2001 or reported by the community to
have opened since then. In 625 (82%) of them, the shop-
keeper was interviewed. 123 shops had closed down com-
pletely, another eight temporarily. Two shop keepers
refused the interview. A total of 195 interviewed shops
were in Ifakara and 430 in the DSS area. The interviewed
shops ranged from little shacks with a grass-thatched roof
to nicely furnished shops with brick walls and display cab-
inets made of glass.
In the DSS area in 2004 we recorded 19 Part II drug stores
and 318 general shops stocking any type of drugs on the
day of the visit (78% of interviewed shops). A further 16
outlets reported having sold drugs during the last month
but were out of stock the day of the interview. As in 2001,
there was no Part I pharmacy in these villages.
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In Ifakara town, there were 10 Part II drug stores and 142
general shops stocking drugs in 2004. One Part I phar-
macy and the hospital pharmacy of St. Francis Designated
District Hospital were not included in the survey. An addi-
tional 7 general shops had sold drugs during the last
month but were out of stock on the day of the interview.
Between 2001 and 2004, the total number of drug-selling
shops increased in the DSS area. There were 15% more
general shops stocking drugs (277 vs. 318) and the
number of drug stores nearly doubled, from 10 to 19. In
both years the absolute number of shops was higher in
Kilombero than in Ulanga District, and the increase varied
also considerably between the two districts: The number
of general shops stocking drugs increased 4% in Ulanga
and 23% in Kilombero. The number of drug shops dou-
bled in Kilombero but remained almost unchanged and
low in Ulanga (Table 1). An analysis of these data in rela-
tion to population numbers is shown below.
Availability of antipyretics and antimalarials in general 
shops
In 2001 and 2004, 99% of general shops stocking drugs in
the DSS had antipyretics/analgesics in stock. In 2004, the
main products stocked in these outlets were paracetamol
generics (93%), aspirin (79%) or co-formulations of para-
cetamol and another antipyretic/analgesic compound
(25%). One particular paracetamol generic made in Tan-
zania (Sheladol™, Shelys Pharmaceuticals Ltd.) was found
in 205 (64%) general shops.
In 2001, of the 277 general shops stocking drugs, 75
(27%) had an antimalarial in stock. All of these stocked
chloroquine, while only 1% of all general shops stocked
SP and less than 1% amodiaquine or quinine. None
stocked injectable antimalarials.
In 2004, of the 318 general shops stocking drugs only 24
(8%) had an antimalarial in stock. 5% stocked amodi-
Table 1: Number of shops selling drugs and antimalarials.
Location Population General 
shops stocking drugs
Drug Stores General 
shops stocking AM
Total of 
AM stocking shops
2001 2004 2001 2004 Change (%) 2001 2004 Change (%) 2001 2004 Change (%) 2001 2004 Change (%)
Ulanga DSS
Idunda 1736 1837 6 5 -17 0 0 1 0 -100 1 0 -100
Igota 1419 1533 6 6 0 0 0 2 0 -100 2 0 -100
Igumbiro 2056 2311 9 10 11 0 0 1 2 100 1 2 100
Iragua 3547 3704 6 8 33 0 1 1 1 0 1 2 100
Kichangani 3119 3103 13 13 0 0 0 1 0 -100 1 0 -100
Kidugalo 1695 2539 7 3 -57 0 0 4 0 -100 4 0 -100
Kivukoni 5634 5612 22 25 14 1 0 -100 4 3 -25 5 3 -40
Lupiro 3591 4009 24 23 -4 1 1 0 0 2 1 3 200
Mavimba 2268 2417 11 15 36 0 0 1 1 0 1 1 0
Milola 1277 1282 3 5 67 0 1 1 0 -100 1 1 0
Minepa 1955 1964 9 7 -22 0 0 2 1 -50 2 1 -50
Nakafulu 1079 919 6 7 17 0 0 0 0 0 0
Sub-total 29376 31230 122 127 4 2 3 50 18 10 -44 20 13 -35
Kilombero DSS
Idete 4657 4661 9 18 100 1 1 0 1 0 -100 2 1 -50
Igima 3210 3793 17 21 24 1 4 300 12 3 -75 13 7 -46
Ikule 1571 2244 10 12 20 1 3 200 4 0 -100 5 3 -40
Kisegese 1113 1370 5 9 80 0 0 3 2 -33 3 2 -33
Lukolongo 3526 3821 9 6 -33 0 0 1 1 0 1 1 0
Mbingu 4928 5380 14 24 71 1 1 0 7 5 -29 8 6 -25
Mchombe 4006 4452 30 37 23 2 3 50 9 0 -100 11 3 -73
Miwangani 1446 1702 7 9 29 0 0 2 2 0 2 2 0
Mkangawalo 4426 4675 15 16 7 1 1 0 9 0 -100 10 1 -90
Mngeta 3218 3399 14 13 -7 0 2 2 1 -50 2 3 50
Mpofu 1673 1897 1 1 0 0 0 0 0 0 0
Namawala 2799 3675 19 19 0 1 1 0 5 0 -100 6 1 -83
Njagi 1597 1678 5 6 20 0 0 2 0 -100 2 0 -100
Sub-total 38170 42747 155 191 23 8 16 100 57 14 -75 65 30 -54
Total DSS 67546 73977 277 318 15 10 19 90 75 24 -68 85 43 -49
Ifakara* 45726 142 10 5 15
Data for the DSS villages of Kilombero and Ulanga Districts and Ifakara town. Ifakara population: National census 2002.
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Table 2: Products stocked by drug stores and general shops in the study area in 2004
(a) Drug stores Number of drug stores with product in stock (percentage)
Location SP AQ QU ART Other INJ Any AM Any AP
Ulanga DSS (N = 3) 3 (100) 3 (100) 3 (100) 0 (0) 0 (0) 3 (100) 3 (100) 3 (100)
Kilombero DSS (N = 16) 14 (88) 15 (94) 11 (69) 0 (0) 1* (6) 10 (63) 16 (100) 16 (100)
Total DSS villages (N = 19) 17 (89) 18 (95) 14 (74) 0 (0) 1 (5) 13 (68) 19 (100) 19 (100)
Ifakara (N = 10) 10 (100) 10 (100) 8 (80) 2 (20) 1** (10) 3 (30) 10 (100) 10 (100)
Total (N = 29) 27 (93) 28 (97) 22 (76) 2 (7) 2 (7) 16 (55) 29 (100) 29 (100)
(b) General shops Number of general shops with product in stock (percentage)
Location SP AQ QU ART Other INJ Any AM Any AP
Ulanga DSS (N = 127) 5 (4) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0) 10 (8) 125 (98)
Kilombero DSS (N = 191) 5 (3) 10 (5) 3 (2) 0 (0) 0 (0) 1 (1) 14 (7) 188 (98)
Total DSS villages (N = 318) 10 (3) 15 (5) 3 (1) 0 (0) 0 (0) 1 (0) 24 (8) 313 (98)
Ifakara (N = 142) 0 (0) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0) 5 (4) 141 (99)
Total (N = 460) 10 (2) 20 (4) 3 (1) 0 (0) 0 (0) 1 (0) 29 (6) 454 (99)
SP = Sulphadoxine-pyrimethamine or sulphalene-pyrimethamine; AQ = Amodiaquine; QU = Quinine; ART = Artesunate; CQ = Chloroquine; INJ = 
Antimalarialinjection; AM = Antimalarial; AP = Antipyretics/analgesics. *Chloroquine; **Includes mefloquine and dihydroartemisinin tablets
aquine, 3% SP and 1% quinine. One general shop had
injectable quinine in stock.
In Ifakara in 2004, all except one of the 142 general shops
stocking drugs had antipyretics/analgesics in stock. Para-
cetamol generics (89%) and co-formulations of paraceta-
mol and another antipyretic/analgesic compound (49%)
were more frequently stocked than aspirin (13%). Only
five (4%) general shops stocking drugs had an antimalar-
ial in stock, all of them amodiaquine.
Hence, within 3 years of the policy change from chloro-
quine to SP, the number of general shops that stocked
antimalarials decreased by 68%, despite an increase in the
number of general shops stocking drugs. The decrease was
more marked in Kilombero (75%) than in Ulanga DSS
area (44%). The proportion of shops stocking drugs that
had antipyretics/analgesics remained unchanged. This
resulted in a considerable increase in the number of gen-
eral shops offering treatment for fever – but no cure for
malaria.
Availability of antipyretics and antimalarials in drug stores
All Part II drug stores in the DSS area stocked antipyretics/
analgesics as well as antimalarial drugs in 2001 and 2004.
In 2004, they all stocked paracetamol generics and 84%
stocked aspirin and diclofenac, a non-steroidal anti-
inflammatory drug.
In 2001, the antimalarials stocked by the 10 drug stores in
the DSS area were chloroquine (80%), SP (70%), quinine
(70%) and amodiaquine (60%). 80% stocked also an
injectable antimalarial.
In 2004, the 19 drug stores stocked mainly amodiaquine
(95%), SP (90%), and quinine (74%). 68% stocked an
injectable antimalarial, usually quinine.
In Ifakara in 2004, all of the 10 drug stores stocked para-
cetamol, 70% diclofenac generics and 40% aspirin. All
drug stores had SP and amodiaquine and 80% had qui-
nine in stock. 30% stocked an injectable antimalarial.
Other antimalarial drugs, such as mefloquine or artesu-
nate were only rarely found (Table 2).
In 2001, the then first-line drug chloroquine was the most
frequently stocked antimalarial in both drug stores and
general shops in the DSS area. In 2004, however, the sec-
ond-line drug amodiaquine was more readily available
than the first-line drug SP. The percentage of drug stores
with the first-line drug in stock was nevertheless higher in
2004 (90% SP) than in 2001 (80% Chloroquine). In
2004, antimalarial injections were less frequently stocked
than in 2001.
Overall access to antimalarials
From 2001 to 2004, the total number of shops with anti-
malarials in stock (including drug stores and general
shops) decreased in the DSS area by almost 50%, from 85
to 43. In 2004, more drug shops than general shops
stocked antimalarials in the Kilombero DSS area and in
Ifakara. By contrast, in the Ulanga DSS area, general shops
Malaria Journal 2006, 5:109 http://www.malariajournal.com/content/5/1/109
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stocking antimalarials outnumbered the few drug shops.
The geographical distribution of antimalarial selling
shops in 2001 and 2004 is displayed in Figure 2.
Reasons for not stocking SP
Of the 50 general shops stocking drugs that were re-visited
in the follow-up study, one had SP and amodiaquine, and
one only amodiaquine in stock the day of the re-visit.
Shops without SP stated no permission to sell (65%), lack
of demand (39%), or inability to buy the drugs (23%) as
reasons for not stocking SP. In total 92% of the shop-
keepers were aware that they were not allowed to sell SP
and 31% of shops without SP had actually tried to buy SP
but could not, usually because they did not have an
appropriate drug store license. These findings suggest that
the respective legislation was implemented quite effec-
tively.
Only after specific probing did 5 shop keepers (10%)
mention the bad reputation or perceived side effects of SP
as reasons for not stocking it. Given that shop-keepers did
report customer demand for antimalarials (51% for SP,
31% for amodiaquine, 24% for quinine and 16% for
chloroquine) it is obvious that there are other determi-
nants for stocking antimalarials than only customer
demand.
Location of antimalarial selling points
While small general shops were found everywhere in the
study area, shops stocking drugs were clustered in larger
centres along with other resources such as permanent
markets and health facilities. Linear regression analysis of
the DSS data showed a significant correlation between the
population of the villages and the number of shops stock-
ing drugs (2001: R2 = 0.46, P < 0.001; 2004: R2 = 0.55, P <
Study area with households (small dots) and number of shops stocking antimalarials, per village, in 2001 and 2004Figure 2
Study area with households (small dots) and number of shops stocking antimalarials, per village, in 2001 and 2004. Data for 
Ifakara town only available for 2004.
Malaria Journal 2006, 5:109 http://www.malariajournal.com/content/5/1/109
Page 8 of 12
(page number not for citation purposes)
0.001) as well as shops stocking antimalarials (2001: R2 =
0.21, P = 0.02; 2004: R2 = 0.28, P = 0.006). Whether or not
there was a drug store in a village was significantly corre-
lated with the size of the village in 2001 (likelihood ratio
χ2 = 13.14, P < 0.001) and 2004 (likelihood ratio χ2 =
7.62, P = 0.006). In both years, there was no such correla-
tion for general shops stocking antimalarials, even though
the number of general shops varied with the size of the vil-
lage.
The distance of households to outlets stocking antimalar-
ials was influenced by the change in the number of outlets
from 2001 to 2004. The increase in number of drug stores
resulted in slightly more households living within a 2 km
range of a drug store (43 vs. 46%)(Figure 3). However, the
number of households within 2 km of any shop selling
antimalarials decreased (Figure 4) as well as the number
of households living near any source of antimalarials –
shops or health facilities (Figure 5). This resulted in more
households being located at a farther distance from a
treatment source (Table 3).
In the DSS area the average population per shop stocking
drugs decreased slightly from 235 in 2001 to 220 in 2004
due to the increase in number of shops. Similarly, the
population per drug store decreased from 6'755 to 3'894,
although it remained very high in Ulanga DSS (10,410 in
2004). The average for Kilombero DSS and Ifakara in
2004 was under the national average of about 6'060 per-
sons per shop selling drugs (calculated on the basis of
[16,20]). The population per shop stocking antimalarials
increased considerably from 795 to 1,720 in the Kilomb-
ero DSS where the numbers of general shops stocking
antimalarials had dropped most markedly. Adding health
facilities to this calculation on the assumption that they
have antimalarial drugs in stock does not change these
ratios significantly (Table 4).
In 2001, of the 25 DSS villages, 12 had a health facility
and a shop stocking antimalarials, 11 villages had only a
shop. In 2 villages with a total population of 2,752 (4% of
DSS) there was no antimalarial selling point at all. In
2004, 10 of the DSS villages had a health facility and a
shop stocking antimalarials, eight had only a shop and
two only a health facility. The number of villages without
either of the two increased to five, with a total population
of 13,506 (18% of total DSS population).
Cumulative percentage of households within given distance to any source of antimalarials (general shops/drug stores/health faciliti s)Figure 5
Cumulative percentage of households within given distance 
to any source of antimalarials (general shops/drug stores/
health facilities).
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Cumulative percentage of households within given distance 
to nearest shop stocking antimalarials (general shops and 
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Discussion & conclusion
In 2001, Tanzania embarked on a malaria treatment pol-
icy change from chloroquine to SP to increase the efficacy
of malaria treatment. Four years later, the number of retail
outlets stocking antimalarials had dropped to almost half
the number in 2001. Furthermore, these outlets did not
primarily stock the first-line antimalarial (SP) but rather
the second-line drug amodiaquine. On the basis of access
measures such as population per antimalarial outlet,
number of villages with at least one antimalarial stockist,
and distance to antimalarial stockists, availability of treat-
ment has declined in 2004 compared to 2001.
This decrease did not affect all outlets equally. The
number of Part II drug stores actually increased and in
these outlets the first line drug SP was more often stocked
in 2004 than chloroquine in 2001. Anecdotal evidence
that some Part II drug stores opened after 2003 were run-
ning on the margins of legality was not investigated in the
frame of this research, although we noticed that all except
one drug seller we interviewed reported to have under-
gone some form of medical training. Most of them were
nurse assistants with one year or less of medical training.
From a regulatory point of view, the restriction to drug
stores must be seen as a positive development, consider-
ing the risks of distributing antimalarials through general
shops [12]. From a public health point of view, this devel-
opment means that the overall number of antimalarial
stocking outlets fell substantially and this bears its own
risk.
Changes in availability did not equally affect the two Dis-
tricts. While the relative decrease was larger in the Kilomb-
ero DSS area, the Ulanga DSS area had a lower number of
shops stocking antimalarials, leaving as many as five out
of 12 villages (42%; 32% of the population) without a
single antimalarial retailer in 2004. Smaller villages in
both districts were more at risk of losing their antimalarial
retailer, as they were more likely to be served only by a
general shop. However, the unit "village" may not always
be absolutely adequate for such calculations, as some vil-
lages are clustered and distances between villages vary
(unpublished observations). A household on the edge of
one village may for example have a shop relatively close
in the neighbouring village.
In Ulanga DSS in 2004, general shops stocking antimalar-
ials outnumbered the few drug stores. The opposite was
the case for the Kilombero DSS area and Ifakara, which
might result in better rates of appropriate treatment in
these areas – under the hypothesis that drug stores pro-
vide better services than general shops. This assumption,
however, does not take into account people's perception
of the different types of shops and their services, and its
impact on utilisation.
The high percentage of general shops stocking antipyretic
drugs (74%) suggests a considerable consumer demand
for drugs against pain or fever. In addition, over 50% of
general shops not stocking antimalarials reported cus-
tomer demand for SP drugs. This unmet demand may be
Table 4: Population per shop.
Kilombero DSS Ulanga DSS Total DSS Ifakara
2001 2004 2001 2004 2001 2004 2004
Population 38170 42747 29376 31230 67546 73977 45726
Population per shop stocking drugs (GS & DS) 234 207 237 240 235 220 301
Population per drug store 4771 2671 14688 10410 6755 3894 4573
Population per shop stocking antimalarials (GS & DS) 587 1425 1469 2402 795 1720 3048
Population per source of antimalarials, including shops and health facilities 530 1155 1088 1562 682 1298 2690
GS = General shop; DS = Drug store
Table 3: Household distance to source of antimalarials
Number of households (percentage)
Drug Store Drug store and general shop stocking AM Health facility and shops stocking AM
Distance (km) 2001 2004 2001 2004 2001 2004
0–2 5191 (43) 5571 (46) 8976 (75) 7671 (64) 9254 (77) 8479 (71)
>2–10 5766 (48) 5309 (44) 3013 (25) 4044 (32) 2735 (23) 3379 (28)
>10 1048 (9) 1125 (9) 16 (0) 290 (2) 16 (0) 147 (1)
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related to temporary non-availability of services and drugs
at health facilities and/or longer distances to the closest
facility or drug store. However, a generally good availabil-
ity of SP in health facilities has been reported since the
policy change [25], but stock-outs occurred recently in
health facilities in the both Kilombero and Ulanga Dis-
tricts.
Interestingly, chloroquine was still requested by patients
who may appreciate its antipyretic effect (lacking in the
case of SP). However, in 2004 only one shop was found to
stock chloroquine, which was officially banned after the
introduction of SP. Recent data on treatment seeking col-
lected by the ACCESS Programme does support the obser-
vation that chloroquine has been effectively banned.
Lack of availability of antimalarials, particularly SP in gen-
eral shops is clearly a result of the new drug regulations.
The negative perceptions of SP because of the fear of
severe side-effects, as described for Tanzania by Nsimba
[26], could not be found in our studies. Interestingly,
shops without antimalarials reported more demand for
SP than for amodiaquine, although other shops stocked
more of the latter. This may reflect the prescription-free
(OTC) status of amodiaquine. Amodiaquine has never
been put on the list of prescription-only drugs, so it may
still be available through non-pharmacy distribution
channels.
Other antimalarial drugs than the ones recommended as
first-, second- or third-line treatment were basically not
available at retailer level. Undoubtedly, the much higher
prices of these drugs limits their availability in rural areas.
In contrast to Dar es Salaam [27], artemisinin-containing
monotherapies are not (yet) frequently sold in our rather
remote rural study area. This is encouraging in view of the
introduction of artemisinin-based combination therapy
(ACT), as widespread use of monotherapies could foster
resistance development [28].
As with every cross-sectional study, our surveys have the
limitation of capturing a certain situation of one point in
the year, ignoring seasonal changes. However, data from
the follow-up survey on reasons for not stocking SP, done
in November 2004, suggest that the survey data are quite
representative. And since the 2001 and 2004 surveys were
done in the same season, the data are at least comparable
over time.
As a result of decreased availability of antimalarials, the
National Malarial Control Programme's goal of improv-
ing prompt access to effective treatment may be difficult
to achieve, considering the importance of the private sec-
tor in providing drugs [10,11,14]. Home-treatment of
malaria with a (mostly) shop bought antimalarial was
shown to be done more rapidly than bringing a child to a
health facility in an area with good availability of antima-
larials in shops [11]. With antipyretic drugs being availa-
ble far closer to people's homes than antimalarials, the
initial treatment is more likely to be done with antipyret-
ics, potentially delaying the administration of an effective
drug against malaria. This is supported by community sur-
vey data from the DSS villages and Ifakara, where on the
day of illness onset, 64% of recent fever cases in children
were treated with an antipyretic but only 53% with an
antimalarial.
However, the interpretation of our data is complicated by
the fact that data from household surveys conducted in
the same areas and time periods did not show a fall in
antimalarial use between 2004 and 2001 (IMPACT-Tz col-
laboration, unpublished data, personal communication
S. Patrick Kachur). There was a (non-significant) fall in the
proportion of general store users obtaining an antimalar-
ial for febrile illness (27% to 13%), but the overall prob-
ability of obtaining an antimalarial showed a (non-
significant) increase (46% to 54%). This reflected mainly
an improvement in antimalarial utilisation for govern-
ment facility users, and the relatively small role of general
stores in antimalarial provision in 2001. The relatively
unimportant role of general stores was documented by
data on antimalarial volumes in 2002, which showed that
general stores accounted for only 7% of all antimalarials
dispensed in the DSS areas [17]. Although poorer people
in these areas are no more likely to use general stores [29],
it is possible that poorer groups were more affected by the
change in antimalarial availability, as they were more
likely to live in the most remote locations. Njau et al. [29]
showed that it is the better-off who get better treatment for
fever episodes. However, they spend significantly more
money for the treatment they obtain from the more
expensive non-governmental organisation facilities and
from drug stores. Changing to better quality but also more
expensive treatment sources may consequently not be an
option for the poorest, unless exemption mechanisms
(theoretically in place in public health facilities) increase
affordability of treatment and care.
The regulatory environment that was created after the
introduction of SP as first-line treatment does not support
well the promotion of home-based management of
malaria. This problem is likely to be further exacerbated
by the imminent policy change in Tanzania with the
introduction of a highly efficacious artemisinin-based
combination therapy (ACT). The potential advantages of
supplying ACT as prescription-only drugs through skilled
providers, such as prevention of fast development of
resistance and limiting irrational drug-use [30], need to be
carefully weighed against the disadvantages of limiting
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ACT distribution to few suppliers, which may not easily be
accessed by a considerable part of the population.
The Accredited Drug Dispensing Outlets (ADDO) Project
which is currently being piloted in a few Tanzanian dis-
tricts by TFDA and Management Sciences for Health may
contribute to the solution to this problem [31]. Its goal is
to improve access to affordable quality drugs and services
in drug retail outlets in rural or peri-urban areas. Activities
include promoting and assisting in the establishment of
new drug stores even in remote areas, and in training drug
sellers and shop owners to dispense a limited range of pre-
scription-only drugs. This initiative could increase the
number of shops licensed to sell antimalarials and/or ACT
in the frame of a quality service provision. A big question
at this time is the high price of ACTs and hence the need
for subsidies to make them affordable in poor rural areas.
To assure prompt and appropriate malaria treatment,
availability of effective drugs close to people's homes is
essential, combined with appropriate prescription prac-
tices and improved compliance on the patient's side. In
case of the imminent policy change to ACT, these issues
need to be taken into consideration. A pre-requisite for
this is a good coordination of the efforts of the drug regu-
latory and the malaria control authorities. The aim must
be to guarantee that the new drugs reach all those who
need them in time. A precious chance would be missed if
regulatory mechanisms prevented people from having
prompt access to life-saving malaria treatment with ACT.
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